JPRN-jRCT2071220113已完成1 期
A pharmacokinetic study of NPC-15 Tablet (for adult use) - NPC-15-10
Eto Takashi0 个研究点目标入组 30 人开始时间: 2023年3月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- Male
入选标准
- •(1) Japanese healthy male subjects aged from 18 to 40 years at the time of obtaining informed consent, or elderly Japanese healthy male subjects aged from 65 to 80 years at the time of obtaining informed consent.(for NPC-15 2.5 mg Elderly Group)
- •(2) Subjects with BMI of 17.6 kg/m2 or more and less than 30.0 kg/m2 at the time of screening as well as on Day -1.
- •(3) Subjects of whom the time of sleep onset is from 21:00 to 25:00 at night and the time of wakeup is from 5:00 to 9:00 in the morning during one week before the study drug administration.
- •(4) Subjects who volunteered for participation in the study by their free will, and of whom the written informed consent was obtained.
- •(5) Subjects who are able to comply with the requirements for the study.
排除标准
- •(1) Subjects who have a past history of hypersensitivity or allergy to melatonin or ramelteon.
- •(2) Subjects with concurrent or a past history of diseases that may affect pharmacokinetic and safety evaluation.
- •(3) Subjects with alcohol dependence or with its past history.
- •(4) Subjects with positive results on drug abuse test (urine drug test) or with a past experience to have used illicit drugs.
- •(5) Subjects who participated in a study for an unapproved medicinal product within 16 weeks prior to the start of study drug administration or in a study for an approved medicinal product within 12 weeks prior to the start of study drug administration, and received other investigational drugs (including placebo).
- •(6) Subjects who performed the following blood donation or blood collection
- •- At least 200 mL of whole blood collection within 4 weeks prior to the start of study drug administration
- •- At least 400 mL of whole blood collection within 12 weeks prior to the start of study drug administration
- •- Blood components donation within 2 weeks prior to the start of study drug administration
- •(7) Subjects who show positive result in any of the tests for HCV antibody, HBs antigen, HIV antigen/antibody, serological test for syphilis or PCR test for COVID-19 infection.
- •(8) Subjects who took any medicinal products or supplements within 2 weeks prior to the start of study drug administration
- •(9) Subjects who have smoked within 24 weeks prior to the start of study drug administration, or who are in the environment of passive smoking on a daily basis.
- •(10)Other subjects who deemed inappropriate for participation in the study by the investigators.
研究者
相似试验
已完成
1 期
Evaluation of blood levels of Paclynap produced drug in Iran in comparison with Abraxan in pancreatic cancer patientsPancreas cancer.Malignant neoplasm of pancreasIRCT2016041118745N4ano Daru Pajuhan Pardis Co20
已完成
不适用
Pharmacokinetic and Pharmacodynamic study of nab-Paclitaxel and solvent-based Paclitaxel in patients with metastatic or recurrent gastric cancerMetastatic or recurrent gastric cancerJPRN-UMIN000030277Shizuoka Cancer Center24
已完成
1 期
Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy VolunteersAttention Deficit Hyperactivity Disorder (ADHD)Neurological - Other neurological disordersACTRN12613001073796Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.20
已完成
1 期
Pharmacokinetic study on N-acetylneuraminic acid in patients with Distal myopathy with rimmed vacuoles (DMRV) - hereditary inclusion body myopathy (hIBM)Distal myopathy with rimmed vacuoles (DMRV) or hereditary inclusion body myopathy (hIBM)JPRN-UMIN000011532Tohoku University Hospital, Department of Neurology9
已完成
1 期
Evaluation of the Pharmacokinetics of Sublingual IPX237 in Healthy VolunteersDepressionACTRN12614000444684Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.24